X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs LUPIN LTD - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA LUPIN LTD SANOFI INDIA/
LUPIN LTD
 
P/E (TTM) x 39.9 28.3 141.2% View Chart
P/BV x 8.6 3.0 291.2% View Chart
Dividend Yield % 1.0 0.6 186.5%  

Financials

 SANOFI INDIA   LUPIN LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
LUPIN LTD
Mar-18
SANOFI INDIA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs4,5601,465 311.3%   
Low Rs4,400727 605.1%   
Sales per share (Unadj.) Rs1,028.5349.6 294.2%  
Earnings per share (Unadj.) Rs129.05.6 2,320.4%  
Cash flow per share (Unadj.) Rs186.029.6 628.8%  
Dividends per share (Unadj.) Rs68.005.00 1,360.0%  
Dividend yield (eoy) %1.50.5 332.7%  
Book value per share (Unadj.) Rs753.6300.3 250.9%  
Shares outstanding (eoy) m23.03452.08 5.1%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x4.43.1 138.9%   
Avg P/E ratio x34.7197.2 17.6%  
P/CF ratio (eoy) x24.137.1 65.0%  
Price / Book Value ratio x5.93.6 162.9%  
Dividend payout %52.790.0 58.6%   
Avg Mkt Cap Rs m103,174495,502 20.8%   
No. of employees `0003.617.0 21.3%   
Total wages/salary Rs m3,59228,647 12.5%   
Avg. sales/employee Rs Th6,537.79,273.6 70.5%   
Avg. wages/employee Rs Th991.41,681.0 59.0%   
Avg. net profit/employee Rs Th819.8147.4 556.0%   
INCOME DATA
Net Sales Rs m23,686158,042 15.0%  
Other income Rs m7081,504 47.1%   
Total revenues Rs m24,394159,545 15.3%   
Gross profit Rs m5,28131,475 16.8%  
Depreciation Rs m1,31310,859 12.1%   
Interest Rs m152,044 0.7%   
Profit before tax Rs m4,66120,076 23.2%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m1,6912,885 58.6%   
Profit after tax Rs m2,9702,513 118.2%  
Gross profit margin %22.319.9 112.0%  
Effective tax rate %36.314.4 252.5%   
Net profit margin %12.51.6 788.7%  
BALANCE SHEET DATA
Current assets Rs m15,673122,095 12.8%   
Current liabilities Rs m6,67850,956 13.1%   
Net working cap to sales %38.045.0 84.4%  
Current ratio x2.32.4 97.9%  
Inventory Days Days7685 89.8%  
Debtors Days Days22120 18.6%  
Net fixed assets Rs m8,098129,876 6.2%   
Share capital Rs m230904 25.5%   
"Free" reserves Rs m17,088134,866 12.7%   
Net worth Rs m17,356135,771 12.8%   
Long term debt Rs m064,245 0.0%   
Total assets Rs m25,400263,054 9.7%  
Interest coverage x311.710.8 2,879.9%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.6 155.2%   
Return on assets %11.81.7 678.5%  
Return on equity %17.11.9 924.7%  
Return on capital %26.93.7 724.2%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14553,141 13.4%   
Fx outflow Rs m6,84619,335 35.4%   
Net fx Rs m29933,807 0.9%   
CASH FLOW
From Operations Rs m3,22617,512 18.4%  
From Investments Rs m-1,555-14,073 11.0%  
From Financial Activity Rs m-1,818-14,921 12.2%  
Net Cashflow Rs m-147-11,482 1.3%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 60.4 0.2 30,200.0%  
Indian inst/Mut Fund % 14.4 11.3 127.4%  
FIIs % 14.6 31.9 45.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 10.1 104.0%  
Shareholders   15,184 98,259 15.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 21, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS